BioAge Labs Inc. Stock Price, News & Analysis

BioAge Labs (NYSE:BIOA) reported Q2 2025 financial results and business updates, highlighting significant progress in its clinical pipeline and discovery platform. The company completed IND-enabling studies for BGE-102, their oral NLRP3 inhibitor for obesity treatment, with Phase 1 trials set to begin in 2H 2025. BioAge expanded its APJ agonist pipeline through a partnership with JiKang Therapeutics and filed patents for novel oral small molecules.

Financial results showed R&D expenses of $19.8M (up from $10.5M in Q2 2024) and a net loss of $21.6M. The company maintains a strong financial position with $313.4M in cash and equivalents, expected to fund operations through 2029.

BioArctic AB (Nasdaq Stockholm: BIOA B) reported that its partner Eisai achieved Leqembi® sales of JPY 23.1 billion in Q2 2025. This generated royalty revenue of SEK 162.5 million for BioArctic, representing a 280% increase compared to Q2 2024.

The quarter's sales included a one-time stockpiling effect of JPY 5.3 billion in the Chinese market due to tariff risks. Excluding this effect, global sales were JPY 17.8 billion, corresponding to royalty revenue of approximately SEK 125 million.

BioArctic AB (NASDAQ Stockholm: BIOA B) and partner Eisai presented compelling new data for lecanemab (Leqembi®) at AAIC 2025, showcasing significant treatment benefits over four years. The data demonstrated that lecanemab slows disease progression by approximately one year compared to no treatment over a four-year period.

Key findings include: 69% of early-stage patients showed improvement or no decline after four years of treatment, an 84% stability or improvement rate in real-world studies, and promising results for a new subcutaneous administration option. The safety profile remained consistent with previous studies, with decreased ARIA rates after initial 12 months.

The real-world study revealed high retention rates of 87%, with 20% of long-term patients improving from mild Alzheimer's to MCI. The new subcutaneous autoinjector showed comparable efficacy to IV administration while offering more convenient at-home treatment options.

BioArctic AB (Nasdaq Stockholm: BIOA B) announced that its partner Eisai will present significant new data on Leqembi® (lecanemab) at the upcoming Alzheimer's Association International Conference (AAIC) in Toronto from July 27-31, 2025.

Key presentations include four-year efficacy and safety data from the Phase 3 Clarity AD Open-Label Extension trial, new data on a subcutaneous formulation for maintenance dosing, and real-world case studies from U.S. clinical settings. Additionally, findings from cerebrospinal fluid samples using a novel immunoassay for measuring Aβ protofibrils will be presented.

Eisai leads the global development and regulatory submissions for Leqembi, with both Eisai and Biogen co-commercializing the product. BioArctic maintains commercialization rights in the Nordic region in partnership with Eisai.

BioArctic AB (Nasdaq Stockholm: BIOA B) announced that its partner Eisai has received the 9th Bioindustry Award from the Japan Bioindustry Association for the drug discovery research of lecanemab (Leqembi®), an antibody treatment for early Alzheimer's disease.

The treatment, co-developed by BioArctic and Eisai, is based on Professor Lars Lannfelt's discoveries about amyloid-beta protein's role in Alzheimer's disease. Lecanemab works by binding to specific forms of amyloid-beta and helping clear it from the brain. Eisai leads the global development and regulatory submissions, with both Eisai and Biogen handling commercialization. BioArctic retains commercialization rights in the Nordic region in partnership with Eisai.

BioArctic (NASDAQ Stockholm: BIOA B) announced that its founder, Professor Lars Lannfelt, will receive the prestigious 2025 Hartwig Piepenbrock-DZNE Prize for his pioneering work in Alzheimer's disease research and the development of lecanemab.

Professor Lannfelt, who founded BioArctic in 2003 with Pär Gellerfors, made groundbreaking discoveries about the role of amyloid-beta protein in Alzheimer's disease. These findings led to the development of lecanemab, an antibody treatment that targets specific forms of amyloid-beta in the brain, developed in collaboration with Eisai. The treatment showed positive results in the global Phase 3 Clarity AD trial.

The award ceremony will take place in Bonn in November 2025. The prize, awarded biennially since 2011, recognizes outstanding research in neurodegenerative disorders.

BioAge Labs (NASDAQ: BIOA) announced new preclinical data presentation at ADA's 85th Scientific Sessions regarding their APJ agonist treatment for diabetic obesity and heart failure. The data shows that APJ activation, combined with incretin therapy, demonstrated significant benefits in preclinical models. Key findings include improved glycemic control with a 25% enhancement in glucose tolerance and reduced HbA1c levels in diabetic obesity models. In heart failure models, the treatment showed cardioprotective effects and reduced cardiac hypertrophy. The company is developing both oral and injectable APJ agonist formulations, targeting an IND filing for 2026. The research suggests APJ agonists could act as exercise mimetics, potentially doubling the weight loss effects of GLP-1 receptor agonists while improving body composition and muscle function.

BioAge Labs (NASDAQ: BIOA) has announced a major expansion of its drug discovery platform through a collaboration with Norwegian diagnostics company Age Labs AS to analyze samples from the HUNT Biobank. The company will profile over 17,000 samples from 6,000+ participants, generating millions of molecular measurements to enhance their proprietary human aging data platform. The analysis will focus on participants who developed cardiometabolic disease (>50%) and cognitive decline/dementia (>35%), using Standard BioTools' SomaScan assay to quantify thousands of proteins per sample. This initiative will complement BioAge's existing platform that contains over 50 million molecular measurements collected across five decades, with exclusive drug discovery rights to the partnership-generated data.

BioArctic announced positive interim safety results for exidavnemab in its Phase 2a EXIST study, enabling progression to higher dose cohorts. The study evaluates exidavnemab as a potential disease-modifying treatment for Parkinson's disease and Multiple System Atrophy (MSA). The first cohort demonstrated that the lower dose was safe and well-tolerated compared to placebo in Parkinson's patients. Two new cohorts will now evaluate higher doses in both Parkinson's and MSA patients. Exidavnemab, a monoclonal antibody, selectively targets pathological alpha-synuclein aggregates while preserving physiological forms. The drug has received orphan drug designation in the US and a positive opinion for orphan medicinal product designation in the EU for MSA treatment. The EXIST study is randomized, double-blinded, and placebo-controlled, evaluating safety, tolerability, pharmacokinetics, and various biomarkers.